Agreement adds new analyzer platforms and expands assay menu across key international markets SAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States. Lifotronic and Q Lifotron

CAIRO and QUEBEC CITY, Canada, Feb. 15, 2026 /PRNewswire/ - OPTEL, a global leader in track-and-trace solutions, and Techno Service, Egypt's premier industrial systems expert, today announced an exclusive partnership. The collaboration delivers a fully localized, end-to-end serialization and aggregation solution for pharmaceutical manufacturers and Third-Party Logistics (3PL) providers, combining OPTEL's proven global technology platform with Techno Service's deep local market expertise. Togethe

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development of this innovative immunotherapy. The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes 15 cohorts evaluating both monotherapy and co

iStock, Malik Evren The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation. For decades, the United States has dominated the global biotech industry, thanks to a policy environment that incentivized American scientists, entrepreneurs and investors to develop novel therapies and medical devices. But counterproductive proposals and decisions—from the courts, from Congress

Through its AI Consortium and global forums, DIA is translating high‑level AI guidance into concrete workflows that match oversight to risk, from low‑stakes automation to decision‑critical regulatory analyses. DIA is a leading global interdisciplinary life science membership association, which drives multi-sector collaboration to speed up medical product development innovation in pursuit of improved patient outcomes. During the 2026 DIA Global Annual Meeting , scheduled to take place in Philad

Crosetto’s technology was recognized as a breakthrough invention by FERMILAB and awarded a $1 million U.S. DOE grant; these achievements, along with other inventions, earned the inventor a U.S. Green Card for ‘Exceptional Ability’ in just 24 hours.DALLAS, Feb. 15, 2026 (GLOBE NEWSWIRE) -- In PDF https://bit.ly/4qCHVYg — The Crosetto Foundation for the Reduction of Cancer Deaths, acting on its mission to provide cost-effective life-saving solutions to the public, calls for an immediate comparat

GLP-1 initiation is associated with a 14.6% reduced risk of asthma exacerbation for overweight patients, 12.2% for obese patients and 13.3% for morbidly obese patients MILWAUKEE, Feb. 15, 2026 /PRNewswire/ -- Glucagon-like peptide-1 receptor agonists (GLP-1) is linked to a significant reduction in asthma exacerbations for overweight, obese and morbidly obese patients without diabetes, according to new research being presented at the 2026 AAAAI Annual Meeting. "Asthma exacerbations can be disrupt

GA, UNITED STATES, February 15, 2026 / EINPresswire.com / -- Myopia progression in children is commonly managed using optical interventions, yet their effectiveness often declines over time. A two-year clinical study evaluated a novel spectacle lens design that integrates arrays of microscopic lenslets to control eye growth. The findings show that wearing these lenses consistently over two years significantly slowed myopia progression and axial elongation compared with standard single-vision cor

NORTHVALE, NJ / ACCESS Newswire / February 13, 2026 / ADM Tronics Unlimited, Inc. (OTCQB: ADMT ), a technology-based developer and manufacturer of innovative technologies and products, announces results for its third fiscal quarter ended December 31, 2025 of Fiscal Year 2026. The upward trend in revenues, as reported in the Company's previous quarterly reports, continues for this third fiscal quarter of fiscal year ended March 31, 2026. For the nine months ended December 31, 2025 revenues inc

SUNDAY, Feb. 15, 2026 — Chemotherapy is one of the most common weapons in the cancer-treatment arsenal, but its side effects are well known. Hair loss. Nausea and vomiting. Mouth sores. Fatigue. The side effects a person with cancer may have are affected by the type of cancer being treated and the chemotherapy drug being used. But a Boston-based cancer specialist told NIH News in Health that there are ways to manage many of them. "Chemotherapy does work," said Dr. Ting Bao , a cancer specialist